Kornimate/medical-research-clean huggingface dataset:
photometric stereo endoscopy (pse) as a tool for imaging the rectum and colon

Conditions: Colonic Polyps

Summary: the goal of this research is to assess photometric stereo endoscopy (pse) as an endoscopic imaging technique. specifically, topographical surface contrast reconstructed from the pse data will be compared to conventional imaging contrast to assess if pse provides enhanced contrast of abnormal tissue.


Eligibility criteria:
inclusion criteria: * patients undergoing a routine colonoscopy screening * patients must be over the age of 18 * patients must be able to give informed consent exclusion criteria: * patients with bleeding/hemostasis disorders * patients that are pregnant * patients taking any anti-coagulants that would preclude them from undergoing a standard of care colonoscopy, such as coumadin and plavix, at the time of the study * patients with known colitis or active bleeding will be excluded

Keywords: colonoscopy
the influence of omega-3 fatty acid on the violence of schizophrenia patient and the possible mechanism

Conditions: Schizophrenia

Summary: investigators plan to explore whether omega-3 fatty acid have effect on the violent behavior of the schizophrenia patients. investigators will use pet to explore the influence on serotonin function of the brain to understand the mechanism of how omega-3 fatty acid works. this study will enroll 100 patients of schizophrenia with violent behavior.participants will be split into two groups randomly. in one group, participants will receive one pill of placebo per day, and in the other, participants will have one pill of 900mg omega-3 fatty acid per day. this intervention will last 3 months.at week 0, week 4, week 8 and week 12, some scales will be evaluated. meanwhile, the density of eicosapentaenoic acid(epa),docosahexaenoic acid (dha),noradrenalin(ne), dopamine(da) and serotonin(5-ht) in blood will be tested.at week 0 and week 12, 10 patients of each group will be randomly selected to have the exam of pet.


Eligibility criteria:
inclusion criteria: * the sore of moas scale \>=4 more than 2 violent behavior in recent 6 months by self repot exclusion criteria: * serious diseases,such as cardiovascular diseases,nervous system disease. allergy to fish oil

Keywords: violence pet omega-3 fatty acid schizophrenia patient
immune signature analysis of disease progression in post immunotherapy lung cancer patients

Conditions: Lung Cancer, Nonsmall Cell

Summary: the purpose of this study is to examine the association between ctdna/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mnsclc.

this is a prospective, non-randomized, pilot study. the target population is adults ≥18 years of age with metastatic non-small cell lung cancer that at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of planned doses of immune checkpoint inhibitor treatment in the first line setting. the study will be conducted at various atrium health wake forest baptist comprehensive cancer center locations. subjects will have blood for ctdna and immune markers collected at baseline, and every 3 months for up to approximately 6 months. blood will be collected at disease progression if it occurs prior to 6 months, ensuring that the collection occurs prior to start of subsequent anti-cancer therapy. we will also collect data from standard of care ct scans every 3 months for up to 6 months or until disease progression. in patients undergoing standard of care biopsies, a portion of tumor tissue will be obtained and tested for tumor mutations. archived tumor tissue collected pre-immunotherapy (if available) will also be tested.

Eligibility criteria:
inclusion criteria 1. informed consent and hipaa authorization for release of personal health information signed by the subject. note: data from tumor samples, blood samples and radiographic scans prior to enrollment date may be used. 2. age greater than or equal to18 years at the time of consent. 3. patients with metastatic non-small cell lung carcinoma have completed first line who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or pembrolizumab combination chemotherapy in the first line setting. 4. patients are allowed to continue maintenance chemotherapy. 5. ability to understand and comply with study procedures for the entire length of the study. 6. known pd-l1 prior to initiation of first-line treatment for nsclc. exclusion criteria 1. enrollment/collection of baseline sample earlier than 7 days prior to scheduled last dose of immune checkpoint inhibitor treatment or more than 30 days after last dose of immune checkpoint inhibitor treatment. 2. patients whose tumors harbor known first line treatment druggable gene abnormalities (e.g. egfr, braf, alk, ros1). 3. patients who have ever received or are currently receiving other types of immunotherapies (nivolumab, ipilimumab, durvalumab or atezolizumab). 4. known pregnancy. 5. patients who progress per the enrolling investigator while on treatment with immune checkpoint inhibitor treatment prior to enrollment.
efficacy and safety of adalimumab in patients with rheumatoid arthritis in routine clinical practice

Conditions: Rheumatoid Arthritis

Summary: observation of safety, tolerability and effectiveness of adalimumab (humira) therapy in a large patient collective under everyday clinical conditions over 2 years.

patients with rheumatoid arthritis who started treatment with adalimumab in a normal clinical setting according to the product label were documented. the follow-up observation period was for 2 years and focused on safety information and maintenance of efficacy during a normal clinical setting. follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.

Eligibility criteria:
inclusion criteria: * moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs, including methotrexate * moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before. in case of incompatibility with methotrexate, humira can be used as monotherapy exclusion criteria: * hypersensitivity against the drug or one of the other ingredients * active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) * moderate to severe cardiac insufficiency

Keywords: safety long-term observation routine clinical setting rheumatoid arthritis effectiveness
breathing versus aerobic exercises on asthma control

Conditions: Asthma

Summary: background: asthma is a chronic inflammatory airway disease characterized by reversible obstruction, inflammation and hyperresponsiveness to different stimulus. aerobic and breathing exercises have been demonstrated to benefit asthmatic patients; however, there is no evidence comparing the effectiveness of the treatments. objective: to compare the effects of aerobic and breathing exercises on clinical control (primary outcome), psychosocial morbidity and daily life physical activity (secondary outcome) in patients with moderate-to-severe persistent asthma. in addition, thoracoabdominal kinematics, heart rate variability and airway and systemic inflammation will be evaluated. the initial hypothesis will be that both exercises present improved clinical control of asthma. methods: forty-eight asthmatic adults will be randomly divided into 2 groups: aerobic (ag) and breathing exercises (bg). all treatments will be performed twice a week for 3 months, totalizing 24 sessions of 40 minutes each. both groups will complete an educational program consisting of 2 classes at the beginning of the interventions. before and after interventions, the following parameters will be quantified: clinical control, health related quality of life, levels of anxiety and depression, maximal exercise capacity, autonomic nervous imbalance, daily living physical activity, thoracoabdominal kinematics, inflammatory cells in the sputum, fraction of exhaled nitric oxide (feno) and systemic inflammatory cytokines. asthma symptoms will be quantified monthly using diaries. kolmogorov-smirnov test will be used to analyze the data normality, and a two-way anova with repeated measures with appropriate post hoc test (student newman keuls) will be used to compare the inter and intra-groups differences

both groups completed an educational program that consisted of two classes held once a week, each lasting 2 hours. presentations and group discussions were done, including information about asthma pathophysiology, medication skills, self-monitoring techniques, and environmental control and avoidance strategies.

Eligibility criteria:
inclusion criteria: * asthma moderate and severe * asthma will diagnosed (global initiative for asthma -gina) * body mass index \<35 kg/ m2 * sedentary * medical treatment, for at least 6 months * clinically stable exclusion criteria: * smokers * cardiac disease * chronic obstructive pulmonary disease * active cancer * pregnant

Keywords: asthma, clinical control, exercise
the role of the thymus in type i diabetes.

Conditions: Type1 Diabetes

Summary: regulatory t lymphocytes play a major role in the protection from autoimmune pathology. defects in immunosuppression mediated by these cells is therefore suspected to contribute to these diseases. this issue has very little been studied in humans.regulatory t cells emigrated from the thymus will be isolated from the blood of patients and healthy controls. the repertoire of antigen-receptors will be analysed by high throughput sequencing and its diversity estimated using appropriate statistical models borrowed from ecology.

in the thymus of an animal model of type i diabetes, the population of regulatory t cells expresses a repertoire of antigen receptors that is approximately ten-fold less diverse than that found in mice resistant to autoimmune pathology. genetic models later showed that this reduced diversity was involved in the susceptibility to diabetes. researchers study the diversity of the tcr expressed by regulatory t cells from paediatric type i diabetes patients and controls. regulatory t cells emigrated from the thymus will be isolated from the blood of patients and healthy controls. the repertoire of antigen-receptors will be analysed by high throughput sequencing and its diversity estimated using appropriate statistical models borrowed from ecology.

Eligibility criteria:
inclusion criteria: * type i diabetes patient * having at least one age-matched sibling (healthy control) exclusion criteria: * other immunopathology * treatment with any anti-inflammatory or immunosuppressive drugs * puberty * legal protection

Keywords: type 1 diabetes juvenile diabetes immune-tolerance regulatory t lymphocyte treg tcr repertoire
cost-effectiveness evaluation of two 10% urea creams in patients with diabetic foot syndrome

Conditions: Diabetic Foot

Summary: randomised, double-blind, cost-effectiveness clinical trial of two 10% urea creams purchased in pharmacies and supermarkets in patients with diabetic foot syndrome.

the aim of this study was to evaluate the cost-effectiveness of two 10% urea creams in patients with diabetic foot syndrome. the methodology was a prospective, longitudinal, single-centre, randomised, double-blind, longitudinal clinical trial that evaluated the skin quality of 20 participating feet belonging to 10 patients with diabetic foot syndrome after the application of two 10% urea creams purchased in pharmacies and supermarkets.

Eligibility criteria:
inclusion criteria: * patients \>18 years with diabetic foot syndrome * deep or superficial sensory neurological involvement diagnosed by semmes-weinstein monofilament and rydel-seiffer tuning fork * abi (ankle brachial index) in normal range * metabolic syndrome * no cognitive impairment * patients who agreed to be included in the study by signing a written consent exclusion criteria: * patients with hypersensitivity or allergy to any of the components of both creams.
maintaining antiviral efficacy after switching to generic entecavir 1 mg for chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: entecavir 1 mg is commonly used in patients with chronic hepatitis b (chb) patients with previous antiviral resistance. this study evaluates the efficacy and safety of switching to generic entecavir 1 mg (baracle®, dong-a science technology) in chb patients taking brand name entecavir 1 mg (baraclude®, bristol-myers squibb) alone or in combination with other nucleos(t)ide analogues after the development of antiviral resistance. the primary aim is virological response (\<20 iu/ml) at 12 months

this study is a prospective single-arm open-label trial. the primary endpoint is virological response (\<20 iu/ml) at 12 months after switching treatment. patients who satisfy the inclusion and exclusion criteria will switch from baraclude® 1 mg to baracle®. assessment of treatment response at 12 months is performed by comparing undetectable hbv dna rates between baseline and 12 months after switching therapy.

Eligibility criteria:
inclusion criteria: * age \>19 years old chb patients * confirmed antiviral resistance * taking brand entecavir 1 mg for more than 1 year * hbv dna \< 20 iu/ml * compensated liver cirrhosis * willing to participate exclusion criteria: * failure to meet the inclusion criteria * cr\>1.5 mg/dl * postive hcv ab * decompensated cirrhosis * pregnant women * hcc * alcoholics
tooth loss in periodontitis patients

Conditions: Periodontitis

Summary: tooth loss in periodontitis patients is associated with patient and site factors as well as with treatment provided. not much is known about long-term tooth loss in periodontitis patients in private practice in the uk. the study plans to follow-up 200 subjects with periodontitis (and currently on maintenance therapy) for 5 years. the effect of treatment provided, site and patient risk factors on tooth loss will be studied.


Eligibility criteria:
inclusion criteria: 1. initial diagnosis of chronic or aggressive periodontitis (lindhe et al. 1999, lang et al. 1999), with at least two sites with ppd and cal ≥5mm 2. diagnosed and treated by the same periodontist (ln) 3. willing to give written informed consent for study participation 4. willing to undergo spt as per standard of care for at least 5 years exclusion criteria: 1. serious medical history that prevents patients from undergoing dental treatment 2. history of rheumatic fever, heart murmur, mitral valve prolapse, artificial heart valve or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures 3. current alcohol or drug abuse 4. self-reported pregnancy or lactation 5. other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may compromise trial participation and/or interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial
investigate the development and progression of lung disease in rheumatoid arthritis over time

Conditions: Rheumatoid Arthritis; Lung Diseases

Summary: the purpose of this study is to investigate the link between the lungs and rheumatoid arthritis (ra). additionally, to understand why ra patients get lung disease, how to treat, and prevent the disease.

this study is to learn more about the risk factors for the development of lung disease among patients with rheumatoid arthritis (ra), an auto-immune disease. additionally, those at heightened risk of developing ra such as in the pre-ra period. this is a prospective and retrospective study, which 420 patients will be enrolled into the study. in-person participation will be up to 4 years, completing different standard of care assessments yearly. additionally, quality of life questionnaires will be completed every 6 months at 4 time points. lastly, an extended follow-up will be performed yearly for an additional 6 years, an overall 10 year participation.

Eligibility criteria:
inclusion criteria: 1. age 18 - 80 years exclusion criteria: 1. subjects who do not speak english 2. subjects without the capacity to sign the informed consent form (icf) 3. pregnant women

Keywords: rheumatoid arthritis interstitial lung disease ra ild
dance workshop on balance of hemiparetic patients

Conditions: Hemiparesis

Summary: the majority of hemiparetic patients have balance disorders, which impact independence in daily living activities and walking. conventional techniques used in rehabilitation improve balance but have shown no effects on dynamic balance required during walking. recently dance is proposed to improve dynamic balance in older people and people with parkinson's disease. although many studies showed that dance is an effective activity to improve balance in these people, it has never been assessed in hemiparetic patients (except a case report). the aim of this study is to show that a dance program improves the balance of hemiparetic patients, compared to a control group. this randomized controlled study aims to include 40 hemiparetic patients who will perform a dance program (experimental group) or a upper-limb rehabilitation program (control group) for 8 one-hour sessions.

randomized controlled study aims to include 40 hemiparetic patients who will perform a dance program (experimental group) or a upper-limb rehabilitation program (control group) for 8 one-hour sessions. these activities are carried out in the form of a workshop and are already proposed in common practice in the service. they are carried out by the physiotherapists of the service. patients are assigned in one of two study groups. it is specified that they will be able to carry out the program of the opposing group at the end of the study in order to limit the "disappointment" effect. the evaluations will be carried out at 4 and 8 weeks and will mainly rely on data of balance, function, quality of life and satisfaction

Eligibility criteria:
inclusion criteria: * patient who signed the consent letter * male or female adults age ≥ 18 years, * hemiparetic patient * patient with balance disorders, able to walk alone and perform a u-turn, with or without technical assistance. exclusion criteria: * bilateral brain lesions, cerebellar syndrome * other pathology or impairment that may interfere with the study such as visual, cardiovascular or other uncontrolled medical conditions * patient who underwent surgery of the musculoskeletal system in the 6 months prior to inclusion * major cognitive disorders not allowing the dance activity or the passing of evaluations * behavioral disorders not allowing group workshops * pregnant woman, breastfeeding * non-affiliation to a social security scheme (beneficiary or beneficiary)

Keywords: stroke balance dance
modified vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection

Conditions: Cirrhosis; Hypertension; Splenectomy; Laparoscopy

Summary: this study aimed to evaluate whether vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection is effective and safe, and to determine whether a reduction in the incidence of postoperative complications of the digestive system improves postoperative quality of life compared with conventional laparoscopic splenectomy and azygoportal disconnection.

after successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. the baseline parameter will be recorded and the patient will be randomized into either interventional (vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection) or control (conventional laparoscopic splenectomy and azygoportal disconnection) group. from postoperative day 3, all patients will receive 100 mg oral aspirin enteric-coated tablets (bayer, leverkusen, germany) once daily for 1 year, low-molecular-weight heparin (cs bio, hebei, china) subcutaneously (4.100 iu/day) for 5 days, and 25 mg of oral dipyridamole (henan furen, henan, china) thrice daily for 3 months. at months 3, 9, and 12 after operation, electron gastroscopy examination for delayed gastric emptying will be done for all patients. postoperative complications of the digestive system (including diarrhea, epigastric fullness, bloating, nausea, and vomiting), liver and renal function, and body weight will be recorded at the seventh day, months 1, 3, 6, 9, and 12 after operation. then one year monitoring will be done in the both groups as per the primary or secondary outcome.

Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis of any etiology * splenomegaly with secondary hypersplenism * bleeding portal hypertension * no evidence of portal vein system thrombosis by ultrasound evaluation and angio-ct * informed consent to participate in the study exclusion criteria: * delayed gastric emptying * diarrhea * hepatocellular carcinoma or any other malignancy, * hypercoagulable state other than the liver disease related * drugs- oral contraceptives, anticoagulation or anti-platelet drugs. * child - pugh c * recent peptic ulcer disease * history of hemorrhagic stroke * pregnancy. * uncontrolled hypertension * age\>75 yrs * human immunodeficiency virus (hiv) infection

Keywords: vagus nerve delayed gastric emptying cirrhosis hypertension laparoscopy